These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9181268)

  • 1. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
    Bittar N
    Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
    Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN
    Clin Ther; 1997; 19(6):1368-78. PubMed ID: 9444446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential properties of mibefradil in hypertension and angina.
    Kobrin I
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
    Viskoper RJ; Bernink PJ; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I
    J Hum Hypertens; 1997 Jun; 11(6):387-93. PubMed ID: 9249234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
    Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
    Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
    Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
    Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
    Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
    Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Introducing mibefradil--a new T-calcium channel blocker].
    Internist (Berl); 1997 Dec; 38(12 Suppl Mibefradil):1-4. PubMed ID: 9437250
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
    Carney S; Wing L; Ribeiro A; Kallwellis R; Zimlichman R; Viskoper RJ; Mion D; Kobrin I
    J Hum Hypertens; 1997 Jul; 11(7):459-66. PubMed ID: 9283064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
    Oparil S
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension.
    Chung O; Hinder M; Sharma AM; Bönner G; Middeke M; Platon J; Unger T
    Fundam Clin Pharmacol; 2000; 14(1):31-41. PubMed ID: 10681072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.